Takeda Receives Marketing Authorization in Canada for NINLARO ™ (ixazomib) in Relapsed/Refractory Multiple Myeloma

NINLARO™ is the first and only oral proteasome inhibitor approved to provide a new treatment option for adult patients living with multiple myeloma in Canada who have received at least one prior therapy
Source: International Myeloma Foundation - Category: Hematology Source Type: news